Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections.
paper
Cited
Public
- Authors
- Lansky, Amy; Finlayson, Teresa; Johnson, Christopher; Holtzman, Deborah; Wejnert, Cyprian; Mitsch, Andrew; Gust, Deborah; Chen, Robert; Mizuno, Yuko; Crepaz, Nicole
- Year
- 2014
- Journal
- PloS one
- PMID
- 24840662
- DOI
- 10.1371/journal.pone.0097596
- PMCID
- PMC4026524
BACKGROUND: Injection drug use provides an efficient mechanism for transmitting bloodborne viruses, including human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Effective targeting of resources for prevention of HIV and HCV infection among persons who inject drugs (PWID) is based on knowledge of the population size and disparity in disease burden among PWID. This study estimated the number of PWID in the United States to calculate rates of HIV and HCV infection. METHODS: We conducted meta-analysis using data from 4 national probability surveys that measured lifetime (3 surveys) or past-year (3 surveys) injection drug use to estimate the proportion of the United States population that has injected drugs. We then applied these proportions to census data to produce population size estimates. To estimate the disease burden among PWID by calculating rates of disease we used lifetime population size estimates of PWID as denominators and estimates of HIV and HCV infection from national HIV surveillance and survey data, respectively, as numerators. We calculated rates of HIV among PWID by gender-, age-, and race/ethnicity. RESULTS: Lifetime PWID comprised 2.6% (95% confidence interval: 1.8%-3.3%) of the U.S. population aged 13 years or older, representing approximately 6,612,488 PWID (range: 4,583,188-8,641,788) in 2011. The population estimate of past-year PWID was 0.30% (95% confidence interval: 0.19 %-0.41%) or 774,434 PWID (range: 494,605-1,054,263). Among lifetime PWID, the 2011 HIV diagnosis rate was 55 per 100,000 PWID; the rate of persons living with a diagnosis of HIV infection in 2010 was 2,147 per 100,000 PWID; and the 2011 HCV infection rate was 43,126 per 100,000 PWID. CONCLUSION: Estimates of the number of PWID and disease rates among PWID are important for program planning and addressing health inequities.
Survey Selection Flowchart for Meta-Analysis.
| # | Section | Preview |
|---|---|---|
| 40 | Discussion | The best available data must be used to guide decision-making for disease prevention. The estimate… |
← Prev
41–41 of 41
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| ArmstrongGL (2007) Injection Drug Users in the United States, 1979–2002. Arch Intern Med 167: 166–173.1724231810.1001/archinte.167.2.166 | — | — | — |
| ArmstrongGL, WasleyA, SimardEP, McQuillanGM, KuhnertWL, et al (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705–14.1670258610.7326/0003-4819-144-10-200605160-00004 | — | — | — |
| BradyJE, FriedmanSR, CooperHLF, FlomPL, TempalskiB, et al (2008) Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. J Urban Health 85(3): 323–351.1834400210.1007/s11524-007-9248-5PMC2329751 | — | — | — |
| Centers for Disease Control and Prevention (1998) Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 47(No. RR–19): 1–39.9790221 | — | — | — |
| Centers for Disease Control and Prevention (2009) Incidence and diagnoses of HIV infection - Puerto Rico, 2006. . MMWR Morb Mortal Wkly Rep. 58(21): 589–591.19498337 | — | — | — |
| Centers for Disease Control and Prevention (2012) Integrated prevention services for HIV infection, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis for persons who use drugs illicitly: Summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Morb Mortal Wkly Rep 61(RR5): 1–43.23135062 | — | — | — |
| Centers for Disease Control and Prevention (2012) Recommendations for the identification of chronic Hepatitis C virus infection among persons born during 1945–1965. MMWR Morb Mortal Wkly Rep 61(No. RR-4): 1–32.22895429 | — | — | — |
| Centers for Disease Control and Prevention. (2011) Risk, prevention, and testing behaviors related to HIV and Hepatitis infections—National HIV Behavioral Surveillance System: Injecting Drug Users, May 2005–February 2006. HIV Special Surveillance Report 7. http://www.cdc.gov/hiv/pdf/statistics_hiv_surveillance_special_report_no_7.pdf Published June 2011. Accessed May 3, 2013. | — | — | — |
| Centers for Disease Control and Prevention. (2011) Viral Hepatitis Surveillance, United States, 2009. http://www.cdc.gov/hepatitis/Statistics/2009Surveillance/index.htm. Accessed February 29, 2012. | — | — | — |
| Centers for Disease Control and Prevention. (2012) Estimated HIV incidence in the United States, 2007–2010. HIV Surveillance Supplemental Report 17 (No. 4). http://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf. Published December 2012. Accessed May 3, 2013. | — | — | — |
| Centers for Disease Control and Prevention. (2012) Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV Surveillance Supplemental Report 17 (No. 3, part A). http://www.cdc.gov/hiv/library/reports/surveillance/2010/surveillance_Report_vol_17_no_3.html. Published June 2012. Accessed May 3, 2013. | — | — | — |
| Centers for Disease Control and Prevention. (2013) HIV Surveillance Report, 2011; vol. 23. http://www.cdc.gov/hiv/library/reports/surveillance/2011/surveillance_Report_vol_23.html. Accessed May 3, 2013. | — | — | — |
| CoadyMH, LatkaMH, ThiedeH, GolubET, OuelletL, et al (2007) Housing status and associated differences in HIV risk behaviors among young injection drug users (IDUs). AIDS Behav 11(6): 854–863.1755182510.1007/s10461-007-9248-1 | — | — | — |
| Comprehensive Meta-Analysis [computer program]. Version Version 2. Englewood, NJ22005. | — | — | — |
| FriedmanSR, TempalskiB, CooperH, PerlisT, KeemM, et al (2004) Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health 81(3): 377–400.1527326310.1093/jurban/jth125PMC3455936 | — | — | — |
| Hedges L, Vevea J. (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods, 3: , 486–504. | — | — | — |
| Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org. Accessed March 7, 2014. | — | — | — |
| HigginsJP, ThompsonSG, DeeksJJ, AltmanDG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414): 557–560.1295812010.1136/bmj.327.7414.557PMC192859 | — | — | — |
| HolmbergSD (1996) The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 86(5): 642–654.862971410.2105/ajph.86.5.642PMC1380471 | — | — | — |
| McQuillanGM, Kruszon-MoranD, GranadeT, FeldmanJW (2010) Seroprevalence of HIV in the US household population aged 18–49 years: The National Health and Nutrition Examination Surveys, 1999–2006. J Acquir Immune Defic Syndr 53(1): 117–123.1971061610.1097/QAI.0b013e3181b3a8e3 | — | — | — |
| PerezCM, MarreroE, MelendezM, AndrovetS, ColonH, et al (2010) Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21–64 years in Puerto Rico. BMC Infect Dis 10: 76.2033188410.1186/1471-2334-10-76PMC2851589 | — | — | — |
| Purcell DW, Johnson CH, Lansky A, Prejean J, Stein R, et al.. (2012) Estimating the population size of men who have sex with men in the United States to develop HIV and syphilis rates. Open AIDS J 6(Suppl 1: M6) 98–107.10.2174/1874613601206010098PMC346241423049658 | — | — | — |
| RaoS, GraubardB, SchmidC, MortonSC, LouisTA, et al (2008) Meta-analysis of survey data: application to health services research. Health Services and Outcomes Research Methodology 8(2): 98–114. | — | — | — |
| Salazar LF, Crosby RA, Holtgrave DR, Head S, Hadsock B, et al.. (2007) Homelessness and HIV-associated risk behavior among African American men who inject drugs and reside in the urban south of the United States. AIDS Behav 11(6 Suppl):70–77.10.1007/s10461-007-9239-217487578 | — | — | — |
| SUDAAN, release 9.1 [computer program]. Research Triangle Park, NC: RTI International; 2004. | — | — | — |
| TempalskiB, PougetER, ClelandCM, BradyJE, CooperHLF, et al (2013) Trends in the population prevalence of people who inject drugs in US Metropolitan Areas 1992–2007. PLOS ONE 8(6): e64789 doi:10.1371/journal.pone.0064789 2375514310.1371/journal.pone.0064789PMC3673953 | — | — | — |
| U.S. Census Bureau. Population estimates [entire dataset]. July 1, 2012. http://www.census.gov/popest/data/. Accessed October 10, 2012. | — | — | — |
| UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. (2010) Guidelines on estimating the size of populations most at risk for HIV. Report # 9789241599580. | — | — | — |
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| KAT2B polymorphism identified for drug abuse in African Americans with regulatory links to drug abuse pathways in human prefrontal cortex. | 2016 | 26202629 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A Brief Motivational Enhancement Intervention to Promote COVID-19 Testing and Vaccination Among People Who Inject Drugs: A Randomized Controlled Trial of Connect2Test. | Mauricio AM et al. | — | 2026 | → |
| Incarceration history and HIV testing among people who inject drugs in the Boston metro area: a pooled cross-sectional study. | Bovell-Ammon BJ et al. | — | 2026 | → |
| A mathematical model of HCV transmission dynamics with sex stratification and environmental effects. | Helikumi M et al. | — | 2025 | → |
| Clinical characteristics and surgical outcomes of spinal infections in intravenous drug users and nonintravenous drug users. | Nishizawa M et al. | — | 2025 | → |
| Common Bacterial Infections in Persons Who Inject Drugs. | Lorenzo MP et al. | — | 2025 | → |
| Comparison of Outcomes of Percutaneous Mechanical Aspiration vs Tricuspid Valve Surgery in Drug Use-Associated Endocarditis of the Tricuspid Valve. | Purcell M et al. | — | 2025 | → |
| Cutaneous Abscess Prevalence and Risk Factors Among People Who Inject Drugs in Denver, Colorado. | Olson NL et al. | — | 2025 | → |
| Estimating the population size of people who inject drugs in Canada, 2021. | Williams A et al. | — | 2025 | → |
| Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis. | Artenie A et al. | — | 2025 | → |
| Integrating HIV prevention services into care settings for people with opioid use disorder (OUD): a study protocol for implementation strategy development and modeling. | Gu M et al. | — | 2025 | → |
| Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs. | Roth AM et al. | — | 2025 | → |
| Assessment of harm reduction receipt and infectious diseases outcomes in United States Veterans with opioid use disorder and history of injection drug use. | Shah KP et al. | — | 2024 | → |
| Estimating the Prevalence of Injection Drug Use Among Acute Hepatitis C Cases From a National Surveillance System: Application of Random Forest-Based Multiple Imputation. | Yin S et al. | — | 2024 | → |
| Infective Endocarditis Among Women Who Inject Drugs. | Adams JA et al. | — | 2024 | → |
| Trends in Hepatitis C Virus and HIV Care Outcomes Among People With HIV in Georgia, United States, 2014-2019. | Evans KN et al. | — | 2024 | → |
| A multimorbidity model for estimating health outcomes from the syndemic of injection drug use and associated infections in the United States. | Chiosi JJ et al. | — | 2023 | → |
| A Note on Preexposure Prophylaxis Preferences Among Women Who Inject Drugs. | Miley KL et al. | — | 2023 | → |
| Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics. | Jawa R et al. | — | 2023 | → |
| Estimated Number of People Who Inject Drugs in the United States. | Bradley H et al. | — | 2023 | → |
| Estimating Causal Effects of HIV Prevention Interventions with Interference in Network-based Studies among People Who Inject Drugs. | Lee T et al. | — | 2023 | → |
| Factors associated with receptive injection equipment sharing among people who inject drugs: findings from a multistate study at the start of the COVID-19 pandemic. | Allen ST et al. | — | 2023 | → |
| Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics. | Moorman AC et al. | — | 2023 | → |
| Integrating harm reduction into acute care: A single center's experience. | Hyde EK et al. | — | 2023 | → |
| La santé sexuelle des hommes trans : entre problèmes de catégorisation et invisibilisation | Rivest P | — | 2023 | → |
| Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress. | Blach S et al. | — | 2023 | → |
| Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs. | Tookes HE et al. | — | 2023 | → |
| Social-spatial network structures among young urban and suburban persons who inject drugs in a large metropolitan area. | Lin Q et al. | — | 2023 | → |
| The relationship of PrEP beliefs to perceived personal, interpersonal and structural benefits and barriers to PrEP use in women who inject drugs. | Paulus K et al. | — | 2023 | → |
| Cancer Screening among Rural People Who Use Drugs: Colliding Risks and Barriers. | Jenkins WD et al. | — | 2022 | → |
| Characterization of Risk Factors Among Individuals with a History of Incarceration Presenting to a Sexually Transmitted Infections Clinic: Implications for HIV and STI Prevention and Care. | Murphy MJ et al. | — | 2022 | → |
| Clinical impact, costs, and cost-effectiveness of hospital-based strategies for addressing the US opioid epidemic: a modelling study. | Barocas JA et al. | — | 2022 | → |
| HIV Risk Among Urban and Suburban People Who Inject Drugs: Elevated Risk Among Fentanyl and Cocaine Injectors in Maryland. | Park JN et al. | — | 2022 | → |
| Impact of Age and Gender Disparity on CD4+ Cell Counts to Control Disease Progression Using Specific HAART in HIV-1 Positive Patients: A Case-Control Study. | Singh A et al. | — | 2022 | → |
| Modeling alcohol use disorder as a set of interconnected symptoms - Assessing differences between clinical and population samples and across external factors. | Huth KBS et al. | — | 2022 | → |
| Participants of a mail delivery syringe services program are underserved by other safe sources for sterile injection supplies. | Hayes BT et al. | — | 2022 | → |
| Research Synthesis, HIV Prevention Response, and Public Health: CDC's HIV/AIDS Prevention Research Synthesis Project. | Koenig LJ et al. | — | 2022 | → |
| Simulated Cost-effectiveness and Long-term Clinical Outcomes of Addiction Care and Antibiotic Therapy Strategies for Patients With Injection Drug Use-Associated Infective Endocarditis. | Adams JW et al. | — | 2022 | → |
| An Evaluation of Opioid Use in Black Communities: A Rapid Review of the Literature. | Jordan A et al. | — | 2021 | → |
| Assessing the relationship between syringe exchange, pharmacy, and street sources of accessing syringes and injection drug use behavior in a pooled nationally representative sample of people who inject drugs in the United States from 2002 to 2019. | Marotta PL et al. | — | 2021 | → |
| Can hepatitis C elimination targets be sustained among people who inject drugs post-2030? | Lanièce Delaunay C et al. | — | 2021 | → |
| Characteristics of late recurrent candidemia in adult patients. | Ala-Houhala M et al. | — | 2021 | → |
| Disparities in risk perception and low harm reduction services awareness, access, and utilization among young people with newly reported hepatitis C infections in California, 2018. | Ohringer AR et al. | — | 2021 | → |
| Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. | Sullivan PS et al. | — | 2021 | → |
| Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond. | Barnett BS et al. | — | 2021 | → |
| Factors Associated with Sterile Syringe Acquisition among People Who Inject Drugs in West Virginia. | Allen ST et al. | — | 2021 | → |
| High Inpatient Health Care Utilization and Charges Associated With Injection Drug Use-Related Infections: A Cohort Study, 2012-2015. | Rapoport AB et al. | — | 2021 | → |
| Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugs. | Tom C et al. | — | 2021 | → |
| Infective Endocarditis Secondary to Injection Drug Use: A Survey of Canadian Cardiac Surgeons. | An KR et al. | — | 2021 | → |
| Intention to initiate and uptake of PrEP among women who injects drugs in a demonstration project: an application of the theory of planned behavior. | Tran NK et al. | — | 2021 | → |
| Invasive Group A Streptococcal Infections Among People Who Inject Drugs and People Experiencing Homelessness in the United States, 2010-2017. | Valenciano SJ et al. | — | 2021 | → |
| "I probably got a minute": Perceptions of fentanyl test strip use among people who use stimulants. | Reed MK et al. | — | 2021 | → |
| Is your syringe services program cost-saving to society? A methodological case study. | Des Jarlais DC et al. | — | 2021 | → |
| Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. | Barocas JA et al. | — | 2021 | → |
| Pharmacy Access to Sterile Injection Supplies for People Who Inject Drugs. | Barnett BS et al. | — | 2021 | → |
| Prevalence and correlates of receptive syringe-sharing among people who inject drugs in rural Appalachia. | White RH et al. | — | 2021 | → |
| Progression and transmission of HIV (PATH 4.0)-A new agent-based evolving network simulation for modeling HIV transmission clusters. | Singh S et al. | — | 2021 | → |
| Reducing Risky Drug Use Behaviors by Enrolling Syringe Exchange Registrants in Methadone Maintenance. | Kidorf M et al. | — | 2021 | → |
| Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky. | Soria J et al. | — | 2021 | → |
| Routes of Administration of Illicit Drugs among Young Swiss Men: Their Prevalence and Associated Socio-Demographic Characteristics and Adverse Outcomes. | Estévez-Lamorte N et al. | — | 2021 | → |
| Syringe Coverage Among People Who Inject Drugs in West Virginia, USA. | Allen ST et al. | — | 2021 | → |
| The Surgical Treatment of Deep Infection in the Native Shoulder Joint. | Henry TW et al. | — | 2021 | → |
| Transition from injecting opioids to smoking fentanyl in San Francisco, California. | Kral AH et al. | — | 2021 | → |
| A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. | Kazemian P et al. | — | 2020 | → |
| "Caballo": risk environments, drug sharing and the emergence of a hepatitis C virus epidemic among people who inject drugs in Puerto Rico. | Abadie R et al. | — | 2020 | → |
| Characterizing latent classes of social support among persons who inject drugs. | Sacamano PL et al. | — | 2020 | → |
| Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. | Tatar M et al. | — | 2020 | → |
| Cotton fever resulting in <i>Enterobacter asburiae</i> endocarditis. | Francis MJ et al. | — | 2020 | → |
| Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. | Krebs E et al. | — | 2020 | → |
| Expansion of Syringe Service Programs in the United States, 2015-2018. | Des Jarlais DC et al. | — | 2020 | → |
| Gender-based vulnerability in women who inject drugs in a harm reduction setting. | Valencia J et al. | — | 2020 | → |
| Hand Infections: Epidemiology and Public Health Burden. | Gundlach BK et al. | — | 2020 | → |
| Health programmes and services addressing the prevention and management of infectious diseases in persons who inject drugs in Canada: a systematic integrative review protocol. | Alvarez E et al. | — | 2020 | → |
| High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department. | Anderson ES et al. | — | 2020 | → |
| HIV Outbreak Control With Effective Access to Care and Harm Reduction in North Carolina, 2017-2018. | Samoff E et al. | — | 2020 | → |
| HIV Pre-exposure Prophylaxis for People Who Inject Drugs: The Context of Co-occurring Injection- and Sexual-Related HIV Risk in the U.S. Northeast. | Edeza A et al. | — | 2020 | → |
| How the evolving epidemics of opioid misuse and HIV infection may be changing the risk of oral sexually transmitted infection risk through microbiome modulation. | Jenkins WD et al. | — | 2020 | → |
| Human Immunodeficiency Virus Testing, Diagnosis, Linkage to Care, and Prevention Services Among Persons Who Inject Drugs, United States, 2012-2017. | Rao S et al. | — | 2020 | → |
| National Public Health Burden Estimates of Endocarditis and Skin and Soft-Tissue Infections Related to Injection Drug Use: A Review. | See I et al. | — | 2020 | → |
| Potential Contributions of Clinical and Community Testing in Identifying Persons with Undiagnosed HIV Infection in the United States. | Kahn JG et al. | — | 2020 | → |
| Preventing transitions into injection drug use: A call for gender-responsive upstream prevention. | Meyers SA et al. | — | 2020 | → |
| Providing reproductive health services for women who inject drugs: a pilot program. | Owens L et al. | — | 2020 | → |
| The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. | Mahmud S et al. | — | 2020 | → |
| The United States' potential blood donor pool: updating the prevalence of donor-exclusion factors on the pool of potential donors. | To L et al. | — | 2020 | → |
| Trends over time in HIV prevalence among people who inject drugs in 89 large US metropolitan statistical areas, 1992-2013. | Williams LD et al. | — | 2020 | → |
| Use of a Standardized Dalbavancin Approach to Facilitate Earlier Hospital Discharge for Vulnerable Patients Receiving Prolonged Inpatient Antibiotic Therapy. | Vazquez Deida AA et al. | — | 2020 | → |
| Use of Population-Based Surveys for Estimating the Population Size of Persons Who Inject Drugs in the United States. | Bradley H et al. | — | 2020 | → |
| Validity of ICD-based algorithms to estimate the prevalence of injection drug use among infective endocarditis hospitalizations in the absence of a reference standard. | McGrew KM et al. | — | 2020 | → |
| What Is the Financial Impact of Orthopaedic Sequelae of Intravenous Drug Use on Urban Tertiary-care Centers? | Dwivedi N et al. | — | 2020 | → |
| Adverse childhood experiences and MSM marijuana use. | Giano Z et al. | — | 2019 | → |
| A good "doctor" is hard to find: Assessing uncredentialed expertise in assisted injection. | Brothers S | — | 2019 | → |
| A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. | Biello KB et al. | — | 2019 | → |
| A Pilot Study of a Mobile App to Support HIV Antiretroviral Therapy Adherence Among Men Who Have Sex with Men Who Use Stimulants. | Horvath KJ et al. | — | 2019 | → |
| Drug Use-Related Normative Misperceptions and Behaviors Among Persons Seeking Heroin Withdrawal Management. | Kenney SR et al. | — | 2019 | → |
| Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. | Crepaz N et al. | — | 2019 | → |
| Factors Associated with Awareness of Pre-exposure Prophylaxis for HIV Among Persons Who Inject Drugs in Philadelphia: National HIV Behavioral Surveillance, 2015. | Roth A et al. | — | 2019 | → |
| Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period? | Jain MK et al. | — | 2019 | → |
| Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance. | Gicquelais RE et al. | — | 2019 | → |
| Heroin type, injecting behavior, and HIV transmission. A simulation model of HIV incidence and prevalence. | Bobashev G et al. | — | 2019 | → |
| Heroin Type, Injecting Behavior, and HIV Transmission. A Simulation Model of HIV Incidence and Prevalence | Bobashev GV et al. | — | 2019 | — |
| HIV infection and frequency of micronucleus in human peripheral blood cells. | Zizza A et al. | — | 2019 | → |
| Increased HIV diagnoses in West Virginia counties highly vulnerable to rapid HIV dissemination through injection drug use: a cautionary tale. | Bradley H et al. | — | 2019 | → |
| Many Opportunities to Record, Diagnose, or Treat Injection Drug-related Infections Are Missed: A Population-based Cohort Study of Inpatient and Emergency Department Settings. | Miller AC et al. | — | 2019 | → |
| Nonviral Injection-Related Injuries in Persons Who Inject Drugs: Skin and Soft Tissue Infection, Vascular Damage, and Wounds. | Pieper B | — | 2019 | → |
| Operative Management of Spinal Infection Among Intravenous Drug Abusers. | Reid DBC et al. | — | 2019 | → |
| Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016. | Toda M et al. | — | 2019 | → |
| Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors. | Jones JM et al. | — | 2019 | → |
| Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. | Coffin PO et al. | — | 2019 | → |
| Sexual risk behaviors and STDs among persons who inject drugs: A national study. | Brookmeyer KA et al. | — | 2019 | → |
| The size estimation of injection drug users (IDUs) using the network scale-up method (NSUM) in Iranshahr, Iran. | Narouee S et al. | — | 2019 | → |
| A Bayesian approach to synthesize estimates of the size of hidden populations: the Anchored Multiplier. | Wesson PD et al. | — | 2018 | → |
| Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement. | Mirzazadeh A et al. | — | 2018 | → |
| Correlates of Injection Drug Use Among Rural Appalachian Women. | Staton M et al. | — | 2018 | → |
| Editor's Spotlight/Take 5: Increased Mortality and Reoperation Rates After Treatment for Septic Arthritis of the Knee in People Who Inject Drugs: Nationwide Inpatient Sample, 2000-2013. | Leopold SS | — | 2018 | → |
| Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. | Hall EW et al. | — | 2018 | → |
| Estimating the number of people who inject drugs: a proposal to provide figures nationwide and its application to France. | Janssen E | — | 2018 | → |
| Hepatitis C virus infection spontaneous clearance: Has it been underestimated? | Ayoub HH et al. | — | 2018 | → |
| HIV Incidence, Prevalence, and Undiagnosed Infections in U.S. Men Who Have Sex With Men. | Singh S et al. | — | 2018 | → |
| Impact of Improved HIV Care and Treatment on PrEP Effectiveness in the United States, 2016-2020. | Khurana N et al. | — | 2018 | → |
| Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders. | Perumalswami PV et al. | — | 2018 | → |
| Infectious Diseases Physicians' Perspectives Regarding Injection Drug Use and Related Infections, United States, 2017. | Rapoport AB et al. | — | 2018 | → |
| Injection Partners, HCV, and HIV Status among Rural Persons Who Inject Drugs in Puerto Rico. | Habecker P et al. | — | 2018 | → |
| Invasive Methicillin-Resistant Staphylococcus aureus Infections Among Persons Who Inject Drugs - Six Sites, 2005-2016. | Jackson KA et al. | — | 2018 | → |
| Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. | Bazzi AR et al. | — | 2018 | → |
| Making the case for harm reduction programs for injection drug users. | Kulikowski J et al. | — | 2018 | → |
| Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. | Biello KB et al. | — | 2018 | → |
| Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. | Barocas JA et al. | — | 2018 | → |
| The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. | Esmaeili A et al. | — | 2018 | → |
| The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. | Mahmud S et al. | — | 2018 | → |
| Using dual capture/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam. | Des Jarlais D et al. | — | 2018 | → |
| Using medical examiner case narratives to improve opioid overdose surveillance. | Hurstak E et al. | — | 2018 | → |
| Addressing the Nation's Opioid Epidemic: Lessons from an Unsanctioned Supervised Injection Site in the U.S. | Kral AH et al. | — | 2017 | → |
| A model to estimate the probability of human immunodeficiency virus and hepatitis C infection despite negative nucleic acid testing among increased-risk organ donors. | Annambhotla PD et al. | — | 2017 | → |
| A Public Health of Consequence: Review of the July 2017 Issue of AJPH. | Galea S et al. | — | 2017 | → |
| Association between alcohol consumption and injection and sexual risk behaviors among people who inject drugs in rural Puerto Rico. | Welch-Lazoritz M et al. | — | 2017 | → |
| Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. | Walters SM et al. | — | 2017 | → |
| HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California. | Page K et al. | — | 2017 | → |
| Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. | Esmaeili A et al. | — | 2017 | → |
| Injection-Related Risk Behavior and Engagement in Outreach, Intervention and Prevention Services Across 20 US Cities. | Mackesy-Amiti ME et al. | — | 2017 | → |
| Lifetime risk of a diagnosis of HIV infection in the United States. | Hess KL et al. | — | 2017 | → |
| National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011. | Salemi JL et al. | — | 2017 | → |
| Prescribing of Human Immunodeficiency Virus (HIV) Pre-exposure Prophylaxis by HIV Medical Providers in the United States, 2013-2014. | Weiser J et al. | — | 2017 | → |
| Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis. | Jordan AE et al. | — | 2017 | → |
| Projected demographic composition of the United States population of people living with diagnosed HIV. | Hood JE et al. | — | 2017 | → |
| Racial/Ethnic Disparities at the End of an HIV Epidemic: Persons Who Inject Drugs in New York City, 2011-2015. | Des Jarlais DC et al. | — | 2017 | → |
| Randomized Controlled Trials of Technology-Based HIV/STI and Drug Abuse Preventive Interventions for African American and Hispanic Youth: Systematic Review. | Córdova D et al. | — | 2017 | → |
| RCT of an integrated CBT-HIV intervention on depressive symptoms and HIV risk. | Tobin K et al. | — | 2017 | → |
| Sociodemographic and access-related correlates of health-care utilization among African American injection drug users: The BESURE study. | Maragh-Bass AC et al. | — | 2017 | → |
| The risk of HIV transmission at each step of the HIV care continuum among people who inject drugs: a modeling study. | Escudero DJ et al. | — | 2017 | → |
| Trends in HIV and HCV Risk Behaviors and Prevalent Infection Among People Who Inject Drugs in New York City, 2005-2012. | Neaigus A et al. | — | 2017 | → |
| Using Network Sampling and Recruitment Data to Understand Social Structures Related to Community Health in a Population of People Who Inject Drugs in Rural Puerto Rico. | Coronado-García M et al. | — | 2017 | → |
| Using technology to assess and intervene with illicit drug-using persons at risk for HIV. | Horvath KJ et al. | — | 2017 | → |
| Contextual Predictors of Injection Drug Use Among Black Adolescents and Adults in US Metropolitan Areas, 1993-2007. | Cooper HL et al. | — | 2016 | → |
| Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. | Hutchinson AB et al. | — | 2016 | → |
| Current Rural Drug Use in the US Midwest. | Dombrowski K et al. | — | 2016 | → |
| Daily alcohol use as an independent risk factor for HIV seroconversion among people who inject drugs. | Young SV et al. | — | 2016 | → |
| Endocarditis as a Marker for New Epidemics of Injection Drug Use. | Keeshin SW et al. | — | 2016 | → |
| Examining the efficacy of a computer facilitated HIV prevention tool in drug court. | Festinger DS et al. | — | 2016 | → |
| HIV Infection Care and Viral Suppression Among People Who Inject Drugs, 28 U.S. Jurisdictions, 2012-2013. | Karch DL et al. | — | 2016 | → |
| Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014. | Blackburn NA et al. | — | 2016 | → |
| KAT2B polymorphism identified for drug abuse in African Americans with regulatory links to drug abuse pathways in human prefrontal cortex. | Johnson EO et al. | — | 2016 | → |
| Low HIV testing among persons who inject drugs-National HIV Behavioral Surveillance, 20 U.S. cities, 2012. | Cooley LA et al. | — | 2016 | → |
| Preoperative evaluation for coronary atherosclerosis with computed tomography angiography in intravenous drug users: an emerging indication in the face of a growing threat. | Prabhakar AM et al. | — | 2016 | → |
| Quantifying Syringe Exchange Program Operational Space in the District of Columbia. | Allen ST et al. | — | 2016 | → |
| Racialized risk environments in a large sample of people who inject drugs in the United States. | Cooper HL et al. | — | 2016 | → |
| Reimagining long-term antibiotics in persons who inject drugs: Time to shift the status quo? | Theisen-Toupal J et al. | — | 2016 | → |
| Risk Environments, Race/Ethnicity, and HIV Status in a Large Sample of People Who Inject Drugs in the United States. | Cooper HL et al. | — | 2016 | → |
| Risky driving and sexual behaviors as developmental outcomes of co-occurring substance use and antisocial behavior. | Luk JW et al. | — | 2016 | → |
| Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. | Hernández D et al. | — | 2016 | → |
| The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. | Durham DP et al. | — | 2016 | → |
| The Importance of Population Denominators for High-Impact Public Health for Marginalized Populations. | Purcell DW et al. | — | 2016 | → |
| The relationships of childhood trauma and adulthood prescription pain reliever misuse and injection drug use. | Quinn K et al. | — | 2016 | → |
| Trends in HIV Infection Among Persons Who Inject Drugs: United States and Puerto Rico, 2008-2013. | Mitsch AJ et al. | — | 2016 | → |
| Trends in Injection Drug Use Among High School Students, U.S., 1995-2013. | Klevens RM et al. | — | 2016 | → |
| A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users. | Smith DK et al. | — | 2015 | → |
| An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. | Perlman DC et al. | — | 2015 | → |
| Bars and nightclubs associated with higher HIV prevalence. | Rossheim ME et al. | — | 2015 | → |
| Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions. | Page K et al. | — | 2015 | → |
| Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? | Perlman DC et al. | — | 2015 | → |
| Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. | Springer SA et al. | — | 2015 | → |
| Estimating the Number of Heterosexual Persons in the United States to Calculate National Rates of HIV Infection. | Lansky A et al. | — | 2015 | → |
| Factors associated with being asked to initiate someone into injection drug use. | Bluthenthal RN et al. | — | 2015 | → |
| Factors Associated with Time Since Last HIV Test Among Persons at High Risk for HIV Infection, National Survey of Family Growth, 2006-2010. | Van Handel M et al. | — | 2015 | → |
| Global Epidemiology of HIV Among Women and Girls Who Use or Inject Drugs: Current Knowledge and Limitations of Existing Data. | Larney S et al. | — | 2015 | → |
| Hepatitis C virus and HIV infections among people who inject drugs in the Middle East and North Africa: a neglected public health burden? | Mumtaz GR et al. | — | 2015 | → |
| Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. | Jordan AE et al. | — | 2015 | → |
| Novel interventions to prevent HIV and HCV among persons who inject drugs. | Coffin PO et al. | — | 2015 | → |
| Population Size Estimates for Men who Have Sex with Men and Persons who Inject Drugs. | Oster AM et al. | — | 2015 | → |